Overview

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
Toxicity of anti-IL-5
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati